Effect of ligustrazine on mice model of hepatic veno-occlusive disease induced by Gynura segetum

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 6, 2011, Pages 1016-1021

  Chen, Zhe ^a   Huo, Ji Rong ^a   Yang, Li ^a   Zhu, Hong Yi ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Gynura segetum; Hepatic veno occlusive disease; Ligustrazine; Tissue factor

Indexed keywords

ALBUMIN; EARLY GROWTH RESPONSE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B P65; TETRAMETHYLPYRAZINE; THROMBOPLASTIN; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTERACEAE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; GYNURA SEGETUM; HISTOPATHOLOGY; LIVER FUNCTION; LIVER VENOOCCLUSIVE DISEASE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 79955917684     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06661.x     Document Type: Article

References (28)

1. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-22.
2. Richardson PG, Guinan EC. The pathology, diagnosis and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br. J. Haematol. 1999; 107: 485-93.
3. Kumar S, Deleve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (Sinusoidal Obstruction Syndrome) after hematopoietic stem cell transplantation. Mayo Clin. Proc. 2003; 78: 589-98.
4. Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs AK. Veno occlusive disease: update on clinical management. World J. Gastroenterol. 2007; 29: 3918-24.
5. Liu CF, Lin CC, Ng LT, Lin SC. Hepatoprotective and therapeutic effects of tetramethylpyrazine on acute econazole-induced liver injury. Planta Med. 2002; 68: 510-14.
6. Zheng H, Chen XL, Han ZX, Wang SY, Chen ZW. Effect of ligustrazine on liver injury after burn trauma. Burns 2006; 32: 328-34.
7. Chang Y, Hsiao G, Chen SH etal. Tetramethylpyrazine suppresses HIF-1α, TNF-α, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacol. Sin. 2007; 28: 327-33.
8. Deleve LD, McCuskey RS, Wang XD etal. Characterization of reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29: 1779-91.
9. Chen MY, Cai JT, Du Q, Wang LJ, Chen JM, Shao LM. Reliable experimental model of hepatic veno-occlusive disease caused by monocrataline. Hepatobiliary Pancreat. Dis. Int. 2008; 7: 395-400.
10. Gao XS, Xiao SS, He JF. Analysis of alkaloids in Sedum aizoon and establishment of hepatic veno-occlusive model in mice. Chin. J. Integr. Tradit. West. Med. Dig. 2006; 14: 311-13.
11. Yuan SQ, Gu GM, Wei TT. Studies on the alkaloids of Gynura segetum (Lour.) Merr. Yaoxue Xuebao 1990; 25: 191-7.
12. Couet CE, Crews C, Hanley AB. Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (symphytum officinale). Nat. Toxins 1996; 4: 163-7.
13. 32P-postlabeling/HPLC method for detection of dehydroretronecine-derived DNA adducts in vivo and in vitro. Chem. Res. Toxicol. 2001; 14: 91-100.
14. Lee JH, Lee KH, Kim S etal. Relevance of protein C and S, antithrombin III von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant. 1998; 22: 883-8.
15. Peres E, Kintzel P, Dansey R etal. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease. Blood Coagul. Fibrinolysis 2008; 19: 203-7.
16. Khoury H, Adkins D, Brown R etal. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant. 2000; 25: 737-43.
17. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008; 41: 229-37.
18. Fearns C, Loskutoff DJ. Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am. J. Pathol. 1997; 150: 579-90.
19. Speiser W, Kapiotis S, Kopp CW etal. Effect of intradermal tumor necrosis factor-α-induced inflammation on coagulation factors in dermal vessel endothelium. Thromb. Haemost. 2001; 85: 362-7.
20. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev. 2003; 17: 63-70.
21. Pihusch V, Pihusch W, Penovici M, Kolb HJ, Hiller E, Pihusch R. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb. Res. 2005; 116: 233-40.
22. Eltumi M, Trivedi P, Hobbs J etal. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropepide of type ? procollagen. Lancet 1993; 342: 518-21.
23. Morabito F, Gentile M, Gay F etal. Insights into defibrotide: an update review. Expert Opin. Biol. Ther. 2009; 9: 763-72.
24. Richardson P, Soiffer RJ, Antin JH etal. Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: final results of a multi-center, randomized, dose-finding trial. Blood 2006; 108: 178.
25. Xiong SL, Wang WB, Wang Q etal. Influence of tetramethylpyrazine on the tissue factor expression induced by TNFα in endothelial cells. China J. Mod. Med. 2007; 17: 2330-3.
26. Rong Y, Hu F, Huang RP etal. Expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006; 66: 7067-74.
27. Moll T, Czyz M, Holzmuller H. Regulation of the tissue factor promoter in endothelial cells. Binding of NF-κB, AP-1, and Sp1-like transcriptional factors. J. Biol. Chem. 1995; 270: 3849-57.
28. Rong Y, Hu F, Huang RP. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006; 66: 7067-74.